Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
SourceCancers, 13, 4, (2021), article 672
Article / Letter to editor
Display more detailsDisplay less details
SubjectAll institutes and research themes of the Radboud University Medical Center; Radboudumc 5: Inflammatory diseases RIHS: Radboud Institute for Health Sciences
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.